News
Novartis’ remibrutinib shows promise for patients with CSU
Novartis has shared positive top-line results from two late-stage studies analysing remibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, among patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.